6 Oct 2017 08:00
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Completion of Acquisition
Total Voting Rights
Director/PDMR Shareholding
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that following admission today of 56,477,285 new ordinary shares of 1 pence each ("Ordinary Shares") relating to the placing to raise approximately £5.5 million and the Company's proposed acquisition of Intelligent Ultrasound Limited for a total consideration of up to £3.6 million, both the placing and the acquisition have completed.
Following admission, the share capital of the Company will consist of 90,701,443 Ordinary Shares. Therefore, the total number of voting rights in the Company is 90,701,443 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.
The Company makes the following disclosures in respect of the participation in the Placing by persons discharging managerial responsibilities and persons closely associated, in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | IP Group plc | |||
2 | Reason for the notification | ||||
a) | Position/status | Person closely associated - David Baynes, Non-Executive Director | |||
b) | Initial notification /Amendment | Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | MedaPhor Group plc
| |||
b) | LEI | N/A | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
Identification code | ISIN: GB00BN791Q39 | ||||
b) | Nature of the transaction | Purchase of ordinary shares of 1 pence each as part of a placing Consideration payable in ordinary shares of 1 pence each as part of an acquisition | |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 12.50 pence | 16,000,000 |
| ||
| 16.22 pence | 5,055,320 |
| ||
|
|
|
| ||
d)
| Aggregated information |
| |||
- Aggregated volume | 16,000,000 (being the placing shares) | ||||
- Price | £2,000,000 | ||||
- Aggregate volume
- Price
|
5,055,320 (being the consideration shares)
£819,972.90 | ||||
e) | Date of the transaction | 6 October 2017 | |||
f) | Place of the transaction | XLON | |||
Enquiries:
MedaPhor Group plc | www.medaphor.com | |
Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 | |
|
| |
Cenkos Securities | Tel: +44 (0)20 7397 8900 | |
Bobbie Hilliam (Nominated Advisor) |
| |
Michael Johnson / Julian Morse (Corporate Broking) |
| |
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com | |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001 | |
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops advanced hi-fidelity haptic and manikin based training simulators, clinical image analysis software tools, augmented reality based needle guidance software and artificial intelligence based automated scanning software for all medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:
Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Point-of-Care simulator platform (launching January 2018). Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound
Focuses on developing augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. ScanNav uses machine-learning based algorithms to automatically access and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.